The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher (CNPV) programme, a fast track for medicines that could deliver a decision on ...
Morningstar analysts do not currently cover PRIFpD, but with our powerful screener, you can find stocks in the same sector,industry, or style and filter on our unbiased ratings and valuation metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results